<DOC>
	<DOCNO>NCT01132638</DOCNO>
	<brief_summary>The aim trial evaluate complete remission erosive gastroesophageal reflux disease pantoprazole magnesium 40 mg daily versus esomeprazole 40 mg daily four-week treatment extension treatment non-responding patient . The study include baseline period 14 day treatment period either 4 week ( 28 -2 + 5 day ) , 8 week depend cure esophagitis due gastroesophageal reflux . The study provide data safety tolerability pantoprazole magnesium .</brief_summary>
	<brief_title>Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg Patients With Erosive Gastroesophageal Reflux Disease</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>Voluntary participation study signature Informed Consent Form ( ICF ) prior specific protocol procedure Patients race On outpatient treatment History frequent symptom crisis related GERD within last 3 month ( least frequency twice week , four eight week ) Diagnosis erosive esophagitis ( grade A D , accord Los Angeles Classification ) In good health condition , except GERD symptom Able follow protocol direction complete daily questionnaire ReQuestâ„¢ throughout study Gastrointestinal disorder , even relate chlorhydropeptic disorder : Barret 's esophagus , peptic ulcer , ZollingerEllison syndrome pyloric stenosis Previous history surgery reduce acid secretion , upper gastrointestinal tract surgery ( except polypectomy cholecystectomy ) At initial endoscopy presenting complicate disorder due erosive esophagitis : obstructive esophageal stenosis , Schatzki ring , esophageal diverticulum , esophageal varix , achalasia hiatal hernia Pregnant woman nurse period Proton Pump Inhibitors ( PPIs ) within last 10 day prior start study Triple therapy base PPIs eradicate H. pylorus within last 28 day prior start study H2blockers , sucralfate prokinetics within last 7 day prior start study Systemic glucocorticoid and/or nonsteroidal antiinflammatory drug ( include COX2 inhibitor ) 3 consecutive day week , within last 28 day prior start study , exception regular intake acetyl salicylic acid dosages 163 mg/day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Gastroesophageal</keyword>
	<keyword>Pantoprazole</keyword>
	<keyword>erosive</keyword>
	<keyword>Erosive GERD grade A-D , acc . Los Angeles classification</keyword>
</DOC>